bstract. One of the fundamental immunologic characteristics of systemic lupus erythematosus (SLE) is a depressed T cell proliferative response to various specific and nonspecific stimuli. Both intrinsic cellular defect(s) and inhibitory influences of humoral factors, e.g., antilymphocyte autoantibodies or immune complexes, have been postulated to underly this functional abnormality. Because patient serum can induce SLE-like T cell dysfunction in normal cells, an extrinsic mechanism is probably responsible, but the nature and site of action of this humoral activity has not been defined. This laboratory recently described a novel antibody specific for activated T cells in SLE, which raised the possibility that suppression of T cell proliferation by SLE serum involved antibodies directed to surface determinants expressed during the process of activation. In experiments to examine this concept further, relatively warm-reactive antibodies to T cell blasts were found to inhibit strongly the well-characterized T cell response to tetanus toxoid. These antibodies were distinct from conventional cold-reactive IgM antibodies to resting T cells, which exhibited little inhibitory activity. Inhibition involved noncytotoxic effects on early activation events at the level of the responding T cell, which markedly reduced the expression of receptors for interleukin 2. Inhibitory effects on antigen-pulsed macrophages or on T cells already committed to proliferate were not demonstrable. Anti-T blast antibodies were characteristic of active SLE and were detected only occasionally in Address reprint requests to Dr. Winfield.
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Introduction
Many immune system functional abnormalities are recognized in systemic lupus erythematosus (SLE),' including defective T cell proliferative response to various specific and nonspecific stimuli (1) (2) (3) (4) ; impaired natural killer (5, 6) , antibody-dependent (7, 8) and T cell-mediated (9, 10) cytotoxicity; failure of suppression in multiple systems (11) (12) (13) (14) (15) ; increased numbers of spontaneously activated B (13, (16) (17) (18) and T (19, 20) cells; and decreased pokeweed mitogen-driven Ig production (13, 18 (21) , which carry over to in vitro experiments.
The available data strongly suggest that antilymphocyte antibodies contribute to certain types of abnormal lymphocyte function in SLE (reviewed in reference 22). The mechanisms by which antibody/lymphocyte interactions result in cellular dysfunction are not well understood, however. Uncertainty persists about the Ig class of the relevant antilymphocyte antibodies, and the requirement of antibodies for complement (C) fixation and cell lysis to exert their functional effects (23) (24) (25) (26) . In addition, several careful studies have failed to demonstrate an association between C-dependent lymphocytotoxic antibody activity and decreased T cell proliferation in different systems despite clear evidence for potent inhibitory activity in SLE serum (21, 27) . Action of immune complexes or IgG antilymphocyte antibodies, which are relatively noncytotoxic in conventional complement-dependent assays (28), usually are invoked to explain such discrepancies.
Recently, this and other laboratories have described antibodies directed to T cell activation antigens in SLE (29) (30) (31) . The existence of such antibodies raises the possibility of an alternate mechanism for suppressive effects of SLE serum on T cell function, i.e., interference with activation events per se by antibodies directed to surface determinants expressed during the process of activation. To examine this concept further, a series of experiments was performed to clarify the role of different types of antilymphocyte antibodies in inhibition of the well-characterized T cell proliferative response to the soluble protein antigen, tetanus toxoid.
Methods
Patients and serum. Peripheral blood was obtained from 20 patients with SLE, 20 patients with rheumatoid arthritis (RA), 20 patients with miscellaneous rheumatic diseases (polymyositis, 3; scleroderma, 4; psoriatic arthritis, 3; osteoarthritis, 5; Reiter's syndrome, 2; and sarcoidosis, Sjogren's syndrome, and gout, I each), and 10 normal subjects. Patients with SLE met the revised diagnostic criteria of the American Rheumatism Association (32) and were unselected except for exclusion of those with prior transfusions or pregnancies. After separation from whole blood, serum was aliquoted and stored at -700C. Each serum aliquot was heated at 560C for 1 h immediately before use. SLE disease activity was assessed as described previously (33) donor, which further reduced day-to-day experimental variability and optimized serum-serum comparisons of inhibitory activity. Percentage inhibition relative to control with sera from 10 normal subjects was negligible: 13±10% for tetanus toxoid-induced proliferation, and 8±11% for PHA-induced proliferation. For certain statistical analyses, limits for significant inhibition were established from these data as >2 SD above the mean values for the normal sera, i.e., >33% for tetanus toxoid-containing cultures and >30% for PHAcontaining cultures.
In certain experiments, plastic adherent peripheral mononuclear cells were pulsed with tetanus toxoid antigen before recombination with T cells according to the technique of Geha et al. (34) . In brief, plastic adherent macrophages (>85% esterase+) were harvested with a rubber policeman, resuspended at a density of 1 X 105 cells/ml in medium containing 6.0 Ag/ml tetanus toxoid and either normal AB serum or SLE serum, and incubated for 18 h in 95% air, 5% CO2 at 370C. The antigen-pulsed macrophages were then washed three times with RPMI 1640, recombined with 2 X I0W T cells (<1% esterase+), purified by passage over nylon wool columns, and cultured in the usual fashion for 5 Preparation ofserum Igfractions. IgG (7S) and IgM (19S) frastions were obtained from serum by sucrose density gradient ultracentrifuigation using acid buffers (glycine-Ha, pH 3.0) as described previously (37) . For certain experiments, IgG was prepared by DEAE cellulose chromatography and IgM was purified by affinity chromatography using anti-IgM-Sepharose 4B. After concentration of fractions to approximately the original serum volume, IgG and IgM concentrations were determined by nephelometry.
Microcytotoxicity. C-dependent microcytotoxicity was performed as previously described (28) Antibodies in SLE sera to surface determinants recognized by the above monoclonal antibodies were sought in experiments to inhibit monoclonal antibody rosette formation. Target lymphocytes (1 X 106) were preincubated with 100 Ml of SLE or normal serum for 1 h at 4VC with frequent agitation. After pelleting and aspiration of serum, the cells were resuspended in the highest dilution of monoclonal antibody, giving near-maximal rosette formation, and rosettes were prepared and enumerated as described above. Inhibition was calculated as follows:
, where a is the percentage rosettes with normal serum preincubation and b is the percentage rosettes with SLE serum preincubation.
The major surface antigen(s) on T cells with which IgM antilymphocyte antibodies in SLE sera react can be modulated, i.e., exhibit decreased fluorescence intensity for SLE IgM staining (Yamada, A., M. Shaw, and J. B. Winfield, submitted for publication). This occurs spontaneously after brief incubations in medium at 370C and is accelerated by SLE serum. Therefore, monoclonal antibody rosette inhibition also was examined in experiments where the target cells were preincubated with SLE serum at 370C for 2 h before rosette assay.
Indirect immunofluorescence and flow cytometry. 1gM and IgG antibody binding to T cells in SLE serum was assessed by indirect immunofluorescence at 4VC using FITC-conjugated rabbit F(ab')2 antibodies to human M-or -y-chains as the second coat. Appropriate dilutions of mouse monoclonal antibodies and FITC-goat F(ab')2 antimouse IgG were used to determine known surface antigens. After they were stained, cells were kept at 4VC and either examined immediately or fixed with paraformaldehyde. Fluorescence intensity and percentage positive cells were determined by flow microfluorometry using an Epics V instrument (Coulter Electronics Inc., Hialeah, FL) equipped with argon laser (488 nm), MDADS and EASY 1 computers, and appropriate software. Laser power, photomultiplier tube amplification, and gain settings were calibrated with fluorospheres (Coulter Electronics Inc.), and kept constant throughout the experimental run on a given lymphocyte preparation. In Figs. 1 and 2 ). Most sera from patients with rheumatoid arthritis and a variety of other non-SLE rheumatic diseases were inactive in this regard.
Inhibition of the tetanus toxoid was not antigen specific, and it involved a saturable, noncytotoxic mechanism. Thus, nine sera also inhibited T cell proliferation induced by diphtheria toxoid to a degree comparable to that observed with tetanus toxoid (62±30 and 65±20%, respectively). Reduction in incorporated (3H]TdR reflected a true inhibition of proliferation rather than a shift in the time course of maximum response, as shown in kinetic experiments with six SLE sera. A plateau occurred with final serum concentrations between 5 and 10%; e.g., in a typical experiment, inhibition with 5, 7.5, and 10% added SLE serum was 65, 79, and 81%, respectively. Cell viability was not reduced in cultures containing SLE serum; i.e., >95% of cells excluded trypan blue in inhibited and control cultures throughout the first 5 d of culture, with a decline to 85-90% on day 6. Cell counts were the same in SLE serum and control cultures from day 0-day 4 but fell to 25-50% of control by day 6. The titer of inhibitory activity was <1:16.
Inhibition of PHA-stimulated T cell proliferation was observed with 8/20 sera but usually was low (mean = 28%), even though suboptimal concentrations of PHA were used. The capacity of sera to inhibit the tetanus toxoid response was not significantly associated with inhibition of the PHA response (P = 0.09 by two-tail Fisher's exact test), primarily because of the relatively larger number of sera (n = 4) that suppressed lacked inhibitory activity. Inhibition by 10 normal sera was negligible (mean±SD = 13±10%). All sera were present continuously from the outset of culture. P = 0.01). This suggested that a common inhibitory effect did indeed exist for SLE serum in both the antigen-and mitogeninduced T cell responses. Modest inhibition of the PHA response was seen with RA and certain miscellaneous rheumatic disease sera, a finding that contrasted with the uniform failure of such sera to inhibit tetanus toxoid-stimulated cultures. These data suggest that SLE serum exerts a quantitatively more potent effect on antigen-induced T cell responses and argue against a major role for nonspecific influences on cellular proliferation in general.
Relationship to SLE disease activity and therapy. Thirteen of the 20 patients with SLE were classified on clinical grounds as having active disease at the time of study. This group had lower CH" levels (mean±SD = 19±15 U/ml; normal, 25-40 U/ml) and were relatively more lymphopenic (694±360 lymphocytes/mm3) than the seven inactive patients (CH50 = 29±9 U/ml; absolute lymphocytes, 1,108±241/mm3). Inhibition of the tetanus toxoid response was higher for active SLE sera (mean±SD = 64±30%) than for inactive SLE sera (10±13%). Such a marked difference in the degree of inhibition was not observed in PHA-stimulated cultures (inhibition by active SLE sera, 34±29%; inhibition by inactive SLE sera, 16±19%).
13 of the patients were being treated with prednisone. Although the average daily dose in 8/11 patients whose sera inhibited the tetanus toxoid responses was higher 20±17 mg/d) than in the 5/9 patient sera that did not (11 10 mg/d), there was little difference in inhibitory activity for sera from corticosteroid-treated and untreated patients (mean inhibition = 52±30 and 42±40%, respectively). Inhibition of the PHA response also was similar in the treated (32±29%) and untreated (20±22%) patients.
Inhibition ofthe tetanus toxoid and PHA responses by SLE serum Ig. The activity in SLE serum that inhibited the tetanus toxoid response was recovered in both IgM and IgG fractions obtained by sucrose density gradient ultracentrifugation using pH 3.5 buffers. In certain sera, both IgM and IgG inhibited the tetanus toxoid response; on a molar basis, however, IgG was less inhibitory than IgM. For example, with two such sera, the final concentrations of IgM giving 50% inhibition were 11 and 40 ,g/ml, whereas 270 and 260 ,u/ml of IgG were required.
In other patients, very low concentrations of IgM were inhibitory, but IgG was inactive (Table I) 15 'C using unstimulated PBMCs as targets. Conversely, 6/9 sera (67%) that did not inhibit the response lacked such antibodies, suggesting that at least one inhibitory component in SLE serum might be an antilymphocyte antibody. Also supporting this possibility was the relative absence of lymphocytotoxic antibodies in the non-SLE sera which, in general, failed to inhibit the tetanus toxoid response (normal sera, 0/10 positive; RA sera, 5/20 positive; and miscellaneous rheumatic disease sera, 3/20 positive).
To define the mononuclear cell specificity of antibodies in SLE serum that might be involved in inhibition of tetanus toxoid-stimulated T cell proliferation, correlative studies were performed using well-characterized PBMC subpopulations and activated T cells as targets. In these experiments, the thermal amplitude of the cytotoxic antibodies was assessed by cold (15'C) and warm (250C) assay temperatures. As shown in Figs. 3 and 4 , a particularly strong relationship was evident for relatively warm-reactive antibodies directed toward T cell blasts (P = 0.006 by two-tail Fishers exact test; Pearson correlation coefficient = 0.67, P = 0.0012). In such 250C assays, the great majority of SLE sera (17/20) were noncytotoxic for unstimulated T cells. However, when cytotoxicity for unstimulated T cells was examined at 150C, a significant, albeit weaker, association between inhibition of the tetanus toxoid response and cold-reactive antibody activity was apparent (Fisher's exact test, P = 0.03). Low levels (<15% killing) of warm-reactive antibodies were detected in only 2/20 RA sera and 3/20 miscellaneous rheumatic disease sera.
The antibodies to activated T cells in sera that inhibited the tetanus toxoid response were predominantly of the IgM class. IgM fractions obtained under immune complex-dissociating conditions from certain strongly inhibitory sera contained anti-T blast cytotoxic activity, whereas highly purified IgG from the same sera did not (Table I) . Conversely, IgM fractions from three patients that lacked the capacity to inhibit the response also lacked anti-T blast antibody. Indirect immunofluorescent staining of T cell blasts in sera inhibiting the tetanus toxoid response was higher for IgM (mean±SD positive cells = 43±30%) than for IgG (percentage positive cells = 4±9%), although staining in the range of -25% was seen with several sera. Affinity purified IgM from a pool of six SLE sera lysed 70% of activated T cells in the presence of complement when assayed at a concentration of 400 Ag/ml, and inhibited the tetanus toxoid response 50% when added to Cytotoxic antibodies to non-T cells obtained as nylon wool-adherent cells (>85% Ia+, 40-70% SIgM+, 15-40% esterase+, and 5-15% OKT3+) were not associated with inhibition of the tetanus toxoid response (P = 0.17). Antibodies to plastic adherent cells, consisting of 80-90% esterase+ monocytes, were demonstrable in only 2/20 SLE sera. In other experiments, SLE sera were examined for their capacity to develop reverse hemolytic plaques by the use of tetanus toxoid and PHA blast cells as targets (37) . Only 6/20 sera developed T-plaque-forming cells, and this was not related to inhibition of the tetanus toxoid response.
Additional evidence to suggest a role for anti-T cell blast antibodies in inhibition of the tetanus toxoid response was obtained in a series of absorption experiments. Four SLE sera with anti-T blast antibodies (cytotoxicity, 50, 55, 80, and 90%) were exhaustively absorbed with nylon wool-enriched resting peripheral T cells, or with tetanus toxoid-or PHA-stimulated T cell blasts, and examined for residual inhibition of the tetanus toxoid response. T cell blasts of either type completely removed the inhibitory activity ( both warm-reactive antibodies cytotoxic for T cell blasts and cold-reactive antibodies to unstimulated T cells. In the converse experiment, absorption with unstimulated T cells decreased warm-reactive cytotoxicity for T cell blasts <10% relative to unabsorbed serum in three patients, and 44% (from 80 to 45% killing) in the fourth. In other experiments, a T cell line (HSB) partially absorbed inhibitory activity from three of four sera, but to a lesser degree than did the peripheral blood T cell blasts. An Ia+ B cell line (2080) removed >95% of inhibitory activity from one serum but not from three others (<5, 10, and 35% reduction relative to unabsorbed serum). These data suggested that inhibition ofthe tetanus toxoid response involved antibody to surface determinants expressed either de novo on activated T cells or in greater density relative to unstimulated cells.
To clarify further the question of specificity for activation neoantigen(s) vs. resting T cell antigen(s), which were relatively increased in density on activated cells, additional absorptions (six instead of two) with unstimulated T cells were performed (Table III) . This procedure reduced the starting IgM concentration by 10%, e.g., from 2.0 to 1.8 mg/ml. As shown, neither warm-reactive cytotoxicity for T cell blasts nor the capacity to inhibit the tetanus toxoid response was eliminated, although a partial reduction in T blast cytotoxicity was observed with one serum.
To demonstrate directly that antibodies to activated T cells inhibited the tetanus toxoid response, eluates were obtained by 37°C incubation of T blasts used for absorption. Each of three eluates inhibited the response: Mi eluate, 71%; Ta eluate, 41%; and He eluate, 35%. Inhibitory activity in the eluates was associated with recovery of warm-reactive cytotoxic antibody against T cell blasts: Mi eluate, 80% killing; and Ta eluate and He eluates, 30% killing. Inhibition was not observed with control eluates.
Kinetics and mechanism of inhibition. As shown in Table  IV , the kinetics of inhibition of the tetanus toxoid response were similar to those observed with L243, a monoclonal anti-DR framework antibody (40) = 21±20%). Exposure to SLE serum after tetanus toxoidpulsed adherent cells and T cells were recombined resulted in inhibition (46±50%) nearly as marked as that seen when PBMCs were cultured with antigen and SLE serum beginning at day 0 (64±34%). These data suggested that SLE serum was acting upon relatively early activation events at the T cell level rather than upon antigen processing by accessory cells.
To elucidate further the mechanism of inhibition, the proportion of cells expressing IL-2 receptors (Tac) and the relative surface membrane density of Tac on T cells during the tetanus toxoid response was determined by indirect immunofluorescence and flow microfluorometry procedures ( 27±12  29±12  56  <10  61  <10  2  25±12  33±15  <10  <10  55  <10  3  31±1  28±12  18  <10  52  <10  4  10±7  20  <10  5  <10  15  <10 * Values for SLE serum represent the mean±SD inhibition for sera from four different patients selected for inhibitory activity in both the tetanus toxoid (tet tox) and PHA responses. The highest dilution of the monoclonal anti-Ia (L243) and anti-Tac antibodies that gave maximum inhibition when added on day 0 was used. Control cultures contained 10% normal AB serum.
6). In control cultures, the percentage of Tac+ cells increased progressively in association with a shift toward staining of higher fluorescence intensity. In SLE serum-inhibited cultures, the expression of Tac was markedly attenuated. Similar results were obtained when Tac+ cells were enumerated by monoclonal antibody rosetting (data not shown). In related experiments, the addition of exogenous IL-2 on day 0 or day 1 dramatically enhanced maximum day 5 [3H]TdR incorporation in control cultures but only partially restored the response in SLE serumcontaining cultures (Fig. 7) . Collectively, these data provide further evidence that the early phase inhibitory effect of SLE serum on peak proliferation involved interference with the initial expression of IL-2 receptors, and, as a consequence, with responsiveness to IL-2. Specificity of antilymphocyte antibodies. Because others have reported antibodies to Ia in SLE sera (30) with potent suppressive effects on T cell proliferative responses involving recognition of Ia determinants (42), autoantibodies to Ia appeared to be particularly attractive candidates to explain the early phase inhibition of the tetanus toxoid response by SLE serum. Several approaches were used in efforts to demonstrate such antibodies. First, pre-incubation of CLL cells (-65% Ia+) or T cell blasts (-20% Ia+) at 40C with the 20 SLE sera before addition of an appropriate dilution of monoclonal anti-DR framework antibody L243 did not inhibit rosette formation between the anti-Ia-coated target cells and goat anti-mouse IgG-coated ox erythrocytes. Mean inhibition in the presence of SLE serum was only 3±5%, well within the range observed with a panel of 10 normal sera, 2±5%. Similar data were obtained with Leu-10, a monoclonal antibody with DS/DC framework specificity. In contrast, both rabbit and chicken anti-Ia antibodies inhibited rosette formation by >95%. As it is possible that the putative anti-Ia antibody in SLE serum must be directed at the identical epitope with which L243 reacts in order to inhibit rosette formation, attempts were this way showed no decrease in L243 rosettes: 41±9 vs. 39±15% in normal human serum control assays. In other experiments, the presence of anti-Ia antibodies was sought in an assay based on inhibition of C-mediated cytotoxicity using chicken anti-Ia antibody, which does not fix C. Pre-incubation of nylon wool-purified non-T cells (85% Ia+) with chicken anti-Ia completely prevented killing by L243 but had no effect on cytotoxicity by the SLE sera.
In studies to be reported in detail separately (42a), antibodies to a number of other cell surface antigens were sought using I effects upon antigen-induced T cell proliferation. First, inhibition of the T cell response to tetanus toxoid was highly correlated with the presence of such antibodies in serum of patients with active disease. Inhibition was not observed with sera from patients with inactive SLE or with non-SLE rheumatic diseases, or with sera from normal subjects that lacked anti-T blast antibodies. Second, both inhibitory activity and cytotoxic antibody to T cell blasts were localized to serum 1g, including fractions isolated by use of immune complex-dissociating conditions. Both IgM and IgG antibodies were identified, although the former was most active. Third, T cell blasts absorbed completely the capacity to inhibit the tetanus toxoid response in parallel with removal of anti-T cell antibody; absorption with resting T cells eliminated cold-reactive cytotoxicity for unstimulated T cells but did not decrease inhibitory activity or anti-T cell blast antibody. Finally, warm-reactive cytotoxic antibody and inhibitory activity were recovered in 370C eluates from activated T cells after absorption at 4VC.
Other factors in SLE serum that potentially could inhibit the tetanus toxoid response include immune complexes, corticosteroids (43), anti-tetanus toxoid antibody, and anti-tetanus toxoid auto-antiidiotypic antibodies (44) . Although some contribution to inhibitory effects of whole serum by immune complexes or corticosteroids is difficult to exclude entirely, such nonantibody factors did not appear to play a significant role. Thus, inhibitory activity could be recovered in Ig fractions that were isolated under immune complex-dissociating conditions and that did not contain demonstrable immune complexes. Heat-aggregated IgG did not inhibit. In addition, inhibitory activity was not removed by ultracentrifugation. There was no relationship between therapy and inhibition of the response, and several of the SLE sera that were most inhibitory were from patients with active disease who were receiving no therapy. Similarly, it is unlikely that inhibition was due to an anti-tetanus toxoid antibody or auto-antiidiotypic antibodies. Tetanus toxoid antibody titers in the SLE patients were not higher than those in normal subjects or patients with non-SLE disorders that did not inhibit. Antibody inhibiting the response could be absorbed completely with PHA-induced T cell blasts, which would not be expected to express the tetanus toxoid idiotype to any significant degree. Tetanus immune globulin had no effect on the response.
Antibodies to T cell blasts have been described previously in RA (45) and SLE (31). In SLE, IgG antibodies react with soluble products of activated T cells. No association of this interesting type of antibody with inhibition of the T cell tetanus toxoid response was apparent, however. In RA, IgM antibodies exhibit increased cytotoxicity for T blasts but can be absorbed completely with unstimulated cells. The absorption data in SLE suggest that anti-T blast antibodies are directed to a neoantigen(s) not expressed on resting T cells, although it remains possible that the preferential activity with T blasts reflects increased surface membrane expression of a determinant also present on unstimulated T cells, but at very low density.
If such were the case, cold-reactive IgM antibodies to resting T cells might also contribute to inhibition of the tetanus toxoid response, as has been suggested previously (46) . Further studies will be required to clarify the relationships among these interesting anti-T cell antibody systems.
The kinetics of inhibition of the T cell response to tetanus toxoid by SLE serum closely paralleled those of anti-Ia. This suggested that anti-T cell antibodies in SLE interfere with the induction of T cell activation, or with early events in the activation phase that take place during the first 24-48 h of culture (47, 48 (51) , and the limited data obtained thus far against the presence of putative Ia specificities, certainly leave open the possibility of Ia blockade. The failure of many SLE sera to inhibit blastogenesis induced by suboptimal concentrations of PHA argues against any interference with delivery of the second signal for T cell activation, i.e., interleukin-l (IL-1) production by macrophages and IL-l/IL-l receptor interaction.
The action of antibody on T cells responding to inductive stimuli is more consistent with the present d~tta. Greater inhibition of the tetanus toxoid response relative to the PHA response could derive simply from a smaller responding cell precursor frequency in the former, as has been shown in other systems (52), even though suboptimal concentrations of PHA and optimal concentrations of tetanus toxoid were used in the cultures. Thus, a common inhibitory influence might exist in both the nonspecific mitogen response and the specific antigenic response, with greater activity on the latter because the number of responding cells is smaller. Perhaps favoring such a common mechanism was the similar efficiency of tetanus toxoid-and PHA-induced T cell blasts to absorb antibody inhibiting the tetanus toxoid response. Furthermore, regression analysis revealed a significant association between inhibition of the two responses by the SLE sera.
It is interesting that the early phase inhibitory activity of SLE anti-T cell blast antibodies reduced the initial expression of IL-2 receptors (Tac+ cells) and markedly attenuated the proliferative response of cultures to additional exogenous IL-2. (Although not approached in this study, the production of IL-2 was probably reduced as well.) The inhibition kinetics here are consistent with interaction of SLE antibody with T cell receptors for antigen or class II molecules (53) (54) (55) , or with IL-2 receptors. Other potential mechanisms requiring further investigation include antibodies to isotypic or clonotypic determinants of the T cell antigen receptor; antibodies to IL-2, although this is unlikely; and antibodies that deliver an off signal analogous to that shown with OKT1 1 (56) .
Our studies concerning the specificity of anti-T blast antibodies provided no evidence for blockade or modulation of the T3, T4, or Tac molecules but were indirect and subject to alternate interpretations. Crucial to the clarification of this issue are experiments to characterize directly the reactive antigen(s) by immunoprecipitation or immunoblotting procedures. Preliminary Western blot data from our laboratory show that SLE antibodies that inhibit the tetanus toxoid response detect several surface membrane molecules on activated T cells that are not apparent on resting gels (unpublished observations). The most prominent of these have approximate molecular weights of 56,000, 51,000 and 32,000. Others recently have identified SLE antibody-reactive glycoproteins by immunoprecipitation with molecular weights of 42,000 and 66,000 on PHA activated peripheral T cells and an adult T cell leukemia line (57) . These proteins appear to be identical with the IL-2 receptor, a finding obviously relevant to the present functional observations. Despite uncertainty about the exact specificity of the antibodies involved, the present observations provide insight into mechanisms underlying certain aspects of immunologic dysfunction in SLE. First, a depressed proliferative response of T cells to soluble antigens and a variety of other specific and nonspecific stimuli is characteristic of cells isolated from patients with this disorder (1) (2) (3) (4) . Our data indicate that such abnormal function can be reproduced, at least with respect to the tetanus toxoid system, in normal lymphocytes through effects of a novel type of antibody to activated T cells. Since most previous investigations have considered only those antibodies that are reactive with resting T cells, the present findings provide an explanation for the failure to define a clear relationship between abnormal cell function and antilymphocyte antibodies to resting T cells (21, 27) .
Because antilymphocyte antibodies in SLE can mediate cell killing in the absence of complement (58, 59) (60) and decreased proliferative response to tetanus toxoid of T cells from patients with SLE (2). Of even greater interest is the idea that auto-antibodies to T cells in this disorder are fundamentally important in pathogenesis, as suggested by their association with lymphopenia (61) , with a variety of T cell functional abnormalities, and with active disease. It will be especially challenging in future studies to determine whether antibodies with the functional effects on T cell activation demonstrated herein reflect an exaggerated homeostatic regulatory mechanism in response to ongoing autoimmune reactions, or play a causal role in the underlying pathogenesis of SLE and related disorders.
